Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(1.06)
# 1859
Out of 5,218 analysts
44
Total ratings
40.48%
Success rate
11.94%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
KalVista Pharma | Reiterates: Overweight | n/a | n/a | n/a | 1 | Dec 9, 2024 | |
Alector | Reiterates: Overweight | n/a | n/a | n/a | 5 | Nov 26, 2024 | |
Annexon | Reiterates: Overweight | n/a | n/a | n/a | 9 | Nov 15, 2024 | |
Verastem | Reiterates: Overweight | n/a | n/a | n/a | 1 | Oct 18, 2024 | |
Vera Therapeutics | Reiterates: Overweight | 107 107 | 44 | 143.18% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 4 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 5 | 4.59 | 8.93% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 13 | 2.03 | 540.39% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 15 | n/a | n/a | 2 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 8 | 12.59 | -36.46% | 1 | Mar 20, 2023 |